Population Pharmacokinetics of Lopinavir and Ritonavir in Combination with Rifampicin-Based Antitubercular Treatment in HIV-Infected Children | Zendy

Chao Zhang | Zendy; Helen McIlleron | Zendy; Yuan Ren | Zendy; JanStefan van der Walt | Zendy; Mats O. Karlsson | Zendy; Ulrika S. H. Simonsson | Zendy; Paolo Denti | Zendy

Open Access

Population Pharmacokinetics of Lopinavir and Ritonavir in Combination with Rifampicin-Based Antitubercular Treatment in HIV-Infected Children

Author(s) -

Chao Zhang,

Helen McIlleron,

Yuan Ren,

JanStefan van der Walt,

Mats O. Karlsson,

Ulrika S. H. Simonsson,

Paolo Denti

Publication year - 2011

Publication title -

antiviral therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.747

H-Index - 87

eISSN - 2040-2058

pISSN - 1359-6535

DOI - 10.3851/imp1915

Subject(s) - lopinavir , lopinavir/ritonavir , ritonavir , rifampicin , pharmacokinetics , medicine , pharmacology , human immunodeficiency virus (hiv) , population , virology , antiretroviral therapy , tuberculosis , viral load , pathology , environmental health

The preferred antiretroviral regimen for young children previously exposed to non-nucleoside reverse transcriptase inhibitors is lopinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors. Rifampicin-based antitubercular treatment reduces lopinavir concentrations. Adding extra ritonavir to lopinavir/ritonavir overcomes the effect of rifampicin, however this approach is not feasible in many settings.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research